Charles River Laboratories International, Inc.
NYSE•CRL
CEO: Mr. James C. Foster J.D.
Sector: Healthcare
Industry: Medical - Diagnostics & Research
Listing Date: 2000-06-23
Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies. It also provides contract vivarium operation services to biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.
Contact Information
Market Cap
$7.65B
P/E (TTM)
-52.1
30.2
Dividend Yield
--
52W High
$228.88
52W Low
$91.86
52W Range
Rank36Top 31.8%
4.5
F-Score
Modified Piotroski Analysis
Based on 10-year fundamentals
Average • 4.5 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2016-2025
Financial Dashboard
Q4 2025 Data
Revenue
$994.23M+0.00%
4-Quarter Trend
EPS
-$5.62+0.00%
4-Quarter Trend
FCF
$58.57M+0.00%
4-Quarter Trend
2025 Annual Earnings Highlights
Key Highlights
Revenue Stable, Cash Flow Up Total revenue $4.02 B, down only 0.9%; operating cash flow $737.6 M, slightly increased from prior year.
DSA Operating Income Strong DSA operating income $424.6 M, a 4.1% decrease; segment margin held steady at 17.7% despite lower volume.
RMS Revenue Increased Modestly RMS revenue grew 2.0% ($16.7 M) driven by large research model product revenue and pricing increases across segments.
Capital Return Focus Repurchased 2.1 million shares for $350.0 M in FY 2025; Board approved new $1.0 B repurchase authorization.
Risk Factors
Operating Income Severely Reduced Operating income fell 88.9% to $25.2 M due to significant asset impairments across multiple segments this fiscal year.
Manufacturing Segment Loss Widens Manufacturing operating loss widened to $(184.3) M, driven by $109.0 M intangible asset impairment charge in CDMO.
Major Asset Impairment Charges Recognized $211.0 M intangible asset impairment in Cell Solutions and CDMO asset groups due to declining operating performance.
Ongoing NHP Litigation Exposure Securities Class Action appeal reversed; derivative lawsuits regarding NHP importation remain stayed pending further developments.
Outlook
Strategic Portfolio Strengthening Focus on strengthening core scientific portfolio via acquisitions; plan to divest non-core assets representing 7% of 2025 revenue.
Key Acquisitions Closing Soon PathoQuest SAS acquisition expected Q1 2026; K.F. (Cambodia) assets acquired in January 2026 to integrate into DSA/RMS supply chains.
Cost Savings Initiatives Underway Implementing restructuring and efficiency actions targeting $300 M cumulative annualized cost savings by end of 2026 through optimization.
CEO Transition Planned CEO/Chair Foster intends to retire effective May 5, 2026; Birgit Girshick unanimously appointed as next Chief Executive Officer.
Peer Comparison
Revenue (TTM)
$13.64B
$13.18B
$11.24B
Gross Margin (Latest Quarter)
68.0%
64.6%
62.4%
Key Metrics
Symbol | Market Cap | P/E (TTM) | ROE (TTM) | Debt to Assets |
|---|---|---|---|---|
| PEN | $13.19B | 73.9 | 13.4% | 12.0% |
| GH | $11.21B | -26.0 | 164.9% | 83.6% |
| DVA | $10.08B | 17.6 | -160.6% | 86.1% |
Long-Term Trends
Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
0.3%
Moderate Growth
4Q Net Income CAGR
N/M
Profitability Shift
Cash Flow Stability
100%
Strong Cash Flow
Deep Research
Next earnings:May 5, 2026
EPS:-
|Revenue:-
Financials
Earnings Calls
Reports
News
Income Statement
Balance Sheet
Cash Flow Statement
Ratios
% Chg.
Income Statement | LTM |
|---|
No Data